Clinical Trial
doi: 10.1038/9498.
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
Affiliations
- PMID: 10371503
- DOI: 10.1038/9498
Item in Clipboard
Clinical Trial
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
Nat Med.
1999 Jun.
Abstract
The size of the pool of resting CD4+ T cells containing replication-competent HIV in the blood of patients receiving intermittent interleukin (IL)-2 plus highly active anti-retroviral therapy (HAART) was significantly lower than that of patients receiving HAART alone. Virus could not be isolated from the peripheral blood CD4+ T cells in three patients receiving IL-2 plus HAART, despite the fact that large numbers of resting CD4+ T cells were cultured. Lymph node biopsies were done in two of these three patients and virus could not be isolated. These results indicate that the intermittent administration of IL-2 with continuous HAART may lead to a substantial reduction in the pool of resting CD4+ T cells that contain replication-competent HIV.
Comment in
-
HIV-1 and HAART: a time to cure, a time to kill.Nat Med. 1999 Jun;5(6):609-11. doi: 10.1038/9452. Nat Med. 1999. PMID: 10371490 No abstract available.
-
Latent reservoirs of HIV infection: flushing with IL-2?Nat Med. 1999 Jun;5(6):611-2. doi: 10.1038/9454. Nat Med. 1999. PMID: 10371491 No abstract available.
Similar articles
-
IL-2 taken to HAART.GMHC Treat Issues. 1999 Feb;13(2):4-6. GMHC Treat Issues. 1999. PMID: 11366116
-
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.Nat Med. 2000 Jul;6(7):757-61. doi: 10.1038/77481. Nat Med. 2000. PMID: 10888923
-
Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).Antivir Ther. 2003 Jun;8(3):233-7. Antivir Ther. 2003. PMID: 12924540 Clinical Trial.
-
HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication.J Leukoc Biol. 2000 Sep;68(3):345-50. J Leukoc Biol. 2000. PMID: 10985250 Review.
-
Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.AIDS Rev. 2006 Apr-Jun;8(2):88-97. AIDS Rev. 2006. PMID: 16848276 Review.
Cited by
-
Attacking the HIV reservoir from the immune and viral perspective.Curr HIV/AIDS Rep. 2013 Mar;10(1):33-41. doi: 10.1007/s11904-012-0150-8. Curr HIV/AIDS Rep. 2013. PMID: 23242702 Review.
-
Innate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation.J Neuroimmune Pharmacol. 2010 Sep;5(3):278-93. doi: 10.1007/s11481-010-9207-x. Epub 2010 Apr 13. J Neuroimmune Pharmacol. 2010. PMID: 20387125 Free PMC article. Review.
-
Activation of HIV-1 proviruses increases downstream chromatin accessibility.iScience. 2022 Nov 8;25(12):105490. doi: 10.1016/j.isci.2022.105490. eCollection 2022 Dec 22. iScience. 2022. PMID: 36505924 Free PMC article.
-
Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs.Gene Ther. 2010 Sep;17(9):1063-76. doi: 10.1038/gt.2010.53. Epub 2010 Apr 22. Gene Ther. 2010. PMID: 20410930 Free PMC article.
-
Regulation of HIV-1 latency by T-cell activation.Cytokine. 2007 Jul;39(1):63-74. doi: 10.1016/j.cyto.2007.05.017. Epub 2007 Jul 20. Cytokine. 2007. PMID: 17643313 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
